Daniela Hosseyni

Daniela Hosseyni

Auto-generated profile, based on publicly available information

Daniela Hosseyni

Late Clinical Development Cellular Therapy, Bristol Myers Squibb, Boudry, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
HHHongxiang Hu
Hongxiang Hu
YLYan Li
Yan Li
JPJulia Piasecki
Julia Piasecki
DHDaniela Hosseyni
Daniela Hosseyni
ZYZhicheng Yan
Zhicheng Yan
YCYiming Cheng
Yiming Cheng
Purpose: Orvacabtagene autoleucel (orva-cel; JCARH125), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, was evaluated in patients with relapsed/refractory multiple myeloma in the EVOLVE phase I/II study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK). Experimental Design: The population PK analysis included 159 patients from the EVOLVE study. Traditional piecewise models, employing a first-order expansion rate with or without lag time followed by a biexponential contraction phase, were compared with a modified model incorporating a cell number-dependent expansion phase aligned with cellular physiology. Covariates assessed encompassed baseline demographics, dose levels (50–600 × 106 CD3+ chimeric antigen receptor+ T cells), prior/concomitant medications, baseline disease burden, and antitherapeutic antibody status. Results: Traditional piecewise models failed to accurately describe maximum orva-cel transgene level (Cmax) and underestimated the time to Cmax (Tmax). Our modified model incorporating a cell number–dependent expansion rate outperformed traditional models by (i) more accurately capturing the cellular expansion phase and (ii) yielding a Tmax that closely matches observed values. Additionally, dose level, percentage of plasma cells in bone marrow, and treatment-induced antitherapeutic antibody were identified as statistically significant covariates and associated with orva-cel expansion and/or persistence. Conclusions: Orva-cel PK was adequately described by the modified piecewise model incorporating a cell number–dependent expansion phase, which aligns closely with T-cell biology.

17 March 2025
Verified
Other
Open access
HHHongxiang Hu
Hongxiang Hu
YLYan Li
Yan Li
JPJulia Piasecki
Julia Piasecki
DHDaniela Hosseyni
Daniela Hosseyni
ZYZhicheng Yan
Zhicheng Yan
YCYiming Cheng
Yiming Cheng
Orva-cel pharmacokinetic profile by flow cytometry (a) and changes in the composition of CAR-T cells post-infusion (b).


17 March 2025
Verified
Other
Open access
HHHongxiang Hu
Hongxiang Hu
YLYan Li
Yan Li
JPJulia Piasecki
Julia Piasecki
DHDaniela Hosseyni
Daniela Hosseyni
ZYZhicheng Yan
Zhicheng Yan
YCYiming Cheng
Yiming Cheng
Correlation between continuous covariates and simulated individual parameters

17 March 2025
Verified
Other
Open access
HHHongxiang Hu
Hongxiang Hu
YLYan Li
Yan Li
JPJulia Piasecki
Julia Piasecki
DHDaniela Hosseyni
Daniela Hosseyni
ZYZhicheng Yan
Zhicheng Yan
YCYiming Cheng
Yiming Cheng
Purpose:Orvacabtagene autoleucel (orva-cel; JCARH125), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, was evaluated in patients with relapsed/refractory multiple myeloma in the EVOLVE phase I/II study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).Experimental Design:The population PK analysis included 159 patients from the EVOLVE study. Traditional piecewise models, employing a first-order expansion rate with or without lag time followed by a biexponential contraction phase, were compared with a modified model incorporating a cell number-dependent expansion phase aligned with cellular physiology. Covariates assessed encompassed baseline demographics, dose levels (50–600 × 106 CD3+ chimeric antigen receptor+ T cells), prior/concomitant medications, baseline disease burden, and antitherapeutic antibody status.Results:Traditional piecewise models failed to accurately describe maximum orva-cel transgene level (Cmax) and underestimated the time to Cmax (Tmax). Our modified model incorporating a cell number–dependent expansion rate outperformed traditional models by (i) more accurately capturing the cellular expansion phase and (ii) yielding a Tmax that closely matches observed values. Additionally, dose level, percentage of plasma cells in bone marrow, and treatment-induced antitherapeutic antibody were identified as statistically significant covariates and associated with orva-cel expansion and/or persistence.Conclusions:Orva-cel PK was adequately described by the modified piecewise model incorporating a cell number–dependent expansion phase, which aligns closely with T-cell biology.